GO:0005160 transforming growth factor beta receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005160 (transforming growth factor beta receptor binding) is a molecular function describing the binding of a ligand to a transforming growth factor beta (TGF-beta) receptor.
• This binding event initiates signaling through TGF-beta receptor complexes, typically composed of type I and type II serine/threonine kinase receptors.
• Ligands such as TGF-beta, activin, and inhibin bind to these receptors with varying specificity, contributing to promiscuous signaling regulation.
• The interaction is critical for diverse cellular processes including wound healing, fibrosis, and immune regulation.
• Dysregulation of TGF-beta receptor binding is implicated in diseases such as cancer, renal arteriolar hyalinosis, and retinoblastoma.
• Research methods to study this function include structural biology, computational modeling, and CRISPR-based gene editing.
Description
Transforming growth factor beta (TGF-beta) receptor binding (GO:0005160) is a molecular function that mediates the initial step of TGF-beta superfamily signaling, where a ligand binds to a TGF-beta receptor on the cell surface. This binding event is essential for transmitting extracellular signals into the cell, influencing a wide array of biological processes such as cell growth, differentiation, and apoptosis. The TGF-beta superfamily includes over 30 ligands, including TGF-beta isoforms, activins, and inhibins, which interact with a limited set of receptors, leading to complex signaling networks. Understanding the specificity and regulation of these interactions is crucial for deciphering normal physiology and disease mechanisms. Researchers study GO:0005160 to elucidate how ligand-receptor binding triggers downstream signaling cascades, often through Smad-dependent and independent pathways. This knowledge is fundamental for developing therapeutic interventions targeting TGF-beta signaling in conditions like fibrosis, cancer, and immune disorders.
transforming growth factor beta receptor binding At A Glance
| GO ID | GO:0005160 |
|---|---|
| GO term | transforming growth factor beta receptor binding |
| Ontology | molecular_function |
| Synonym | activin, inhibin, TGF-beta receptor binding, TGFbeta receptor binding, transforming growth factor beta, transforming growth factor beta ligand binding to type II receptor, transforming growth factor beta ligand binding to type I receptor, transforming growth factor beta receptor anchoring activity, transforming growth factor beta receptor ligand |
| Major function | Binding to a transforming growth factor beta receptor, initiating signaling. |
| Ligand examples | TGF-beta, activin, inhibin |
| Receptor types | Type I and type II serine/threonine kinase receptors |
| Downstream pathways | Smad-dependent and Smad-independent signaling |
What Is GO:0005160?
According to the Gene Ontology, GO:0005160 is defined as the binding to a transforming growth factor beta receptor. This molecular function encompasses the interaction between a ligand (such as TGF-beta, activin, or inhibin) and a TGF-beta receptor, which can be a type I or type II receptor. The binding is a prerequisite for receptor activation and subsequent intracellular signaling. Synonyms include activin binding, inhibin binding, TGF-beta receptor binding, and TGFbeta receptor binding, reflecting the broader ligand specificity within the TGF-beta superfamily.
Why Is transforming growth factor beta receptor binding Important in Cell Biology?
GO:0005160 is fundamental to understanding how cells respond to TGF-beta superfamily ligands, which control a myriad of biological processes from embryonic development to tissue homeostasis. Dysregulation of this binding event is associated with numerous pathologies, including cancer, fibrosis, and autoimmune diseases. Therefore, studying this function provides insights into disease mechanisms and identifies potential therapeutic targets.
• Initiates TGF-beta signaling, a key pathway in cell growth, differentiation, and apoptosis.
• Mediates wound healing and myofibroblast differentiation, as shown in skin wound healing models.
• Implicated in renal arteriolar hyalinosis induced by tacrolimus, linking to kidney disease.
• Loss of TGF-beta receptor binding contributes to retinoblastoma pathogenesis.
• Plays a role in immune regulation and inflammation.
• Target for cancer therapy, as TGF-beta signaling promotes tumor progression and metastasis.
• Involved in fibrosis and tissue remodeling.
• Subject of structural studies to design kinase inhibitors like SB505124.
• Computational models help predict promiscuous ligand-receptor interactions.
• Internalization and trafficking of ligand-receptor complexes regulate signaling duration.
Molecular Mechanism of transforming growth factor beta receptor binding
Ligand Recognition and Binding
In simple terms: A ligand molecule docks onto a receptor on the cell surface.
The binding of TGF-beta superfamily ligands to their receptors is a highly specific yet promiscuous process. Ligands such as TGF-beta, activin, and inhibin bind to type I and type II receptors with varying affinities. The binding typically involves the ligand interacting with both receptor types to form a ternary complex, which is essential for signaling. Structural studies have revealed that the type I receptor kinase domain can be targeted by inhibitors like SB505124, highlighting the druggability of this interaction.
Receptor Complex Assembly
In simple terms: The ligand brings together two types of receptors to form an active signaling unit.
Upon ligand binding, type II receptors recruit and phosphorylate type I receptors, leading to the formation of a heterotetrameric complex. This assembly is critical for propagating the signal. Computational modeling has been used to simulate the formation of TGF-beta and activin A receptor complexes, providing insights into how promiscuous signaling is regulated.
Internalization and Trafficking
In simple terms: The receptor-ligand complex is taken into the cell, where it can continue signaling or be degraded.
After binding, the ligand-receptor complexes are internalized via endocytosis, as demonstrated in BALB/c 3T3 fibroblasts. This internalization can either enhance or attenuate signaling depending on the cellular context. The trafficking of these complexes is a regulatory step that controls the duration and intensity of TGF-beta signaling.
Downstream Signaling Activation
In simple terms: The activated receptor sends signals to the nucleus via Smad proteins.
The activated type I receptor phosphorylates receptor-regulated Smads (R-Smads), which then form complexes with co-Smad and translocate to the nucleus to regulate gene expression. This canonical pathway is central to TGF-beta function, but non-Smad pathways such as MAPK also contribute, as seen in p38-dependent myofibroblast differentiation.
Key Genes Involved in GO:0005160 transforming growth factor beta receptor binding
The following genes and proteins are key players in transforming growth factor beta receptor binding and its downstream signaling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TGFB1 | Ligand that binds to TGF-beta receptors | Central to fibrosis and cancer |
| TGFBR1 | Type I receptor kinase, propagates signal | Target for inhibitors like SB505124 |
| TGFBR2 | Type II receptor kinase, binds ligand and activates type I | Loss linked to retinoblastoma |
| ACVR1 | Activin receptor type I | Involved in promiscuous signaling |
| ACVR2A | Activin receptor type IIA | Mediates activin signaling |
| INHBA | Inhibin beta A subunit | Ligand for activin receptors |
| SMAD2 | R-Smad downstream of TGF-beta | Transduces signals to nucleus |
| SMAD3 | R-Smad downstream of TGF-beta | Regulates gene expression |
| SMAD4 | Co-Smad, common to TGF-beta superfamily | Essential for Smad complex |
| MAPK14 | p38 MAPK, non-Smad pathway | Drives myofibroblast differentiation |
| HAS1 | Hyaluronan synthase 1 | Modulates TGF-beta signaling in wound healing |
| HAS3 | Hyaluronan synthase 3 | Modulates TGF-beta signaling in wound healing |
| FKBP1A | FKBP12, binds type I receptor | Regulates receptor activation |
| BAMBI | Pseudoreceptor, inhibits signaling | Negative regulator of TGF-beta |
| LTBP1 | Latent TGF-beta binding protein | Controls ligand availability |
| SERPINE1 | PAI-1, target gene of TGF-beta | Marker of TGF-beta activity |
| CDKN1A | p21, target gene of TGF-beta | Mediates cell cycle arrest |
| JUNB | Target gene of TGF-beta | Immediate early response |
How Is transforming growth factor beta receptor binding Regulated?
The binding of TGF-beta to its receptors is tightly regulated at multiple levels. Extracellularly, latent TGF-beta binding proteins (LTBPs) sequester the ligand in the matrix, controlling its availability. Membrane-bound co-receptors like betaglycan and endoglin modulate ligand presentation to the signaling receptors. Intracellularly, inhibitory proteins such as FKBP12 and BAMBI can prevent receptor activation. Additionally, internalization and degradation of receptors provide feedback regulation. Post-translational modifications, including phosphorylation and ubiquitination, also influence receptor stability and function.
transforming growth factor beta receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TGFBR2 | Retinoblastoma | Knockout in retinoblastoma cell lines |
| TGFBR1 | Cancer, fibrosis | Point mutation to study kinase inhibition |
| TGFB1 | Fibrosis, cancer | Overexpression in fibroblasts |
| HAS1/HAS3 | Skin wound healing | Double knockout mice |
| ACVR1 | Promiscuous signaling | Knock-in of mutations |
Cancer
Dysregulated TGF-beta receptor binding is a hallmark of many cancers. In retinoblastoma, lack of TGF-beta type II receptor expression contributes to tumorigenesis. In other cancers, TGF-beta signaling can promote epithelial-mesenchymal transition, invasion, and metastasis. Targeting the binding interaction with inhibitors like SB505124 is a therapeutic strategy.
Renal Arteriolar Hyalinosis
Tacrolimus-induced renal arteriolar hyalinosis involves endothelial cell TGF-beta receptor activation, leading to vascular damage. This highlights the role of TGF-beta receptor binding in drug-induced nephrotoxicity.
Fibrosis and Wound Healing
TGF-beta receptor binding drives myofibroblast differentiation during skin wound healing, as shown in mice lacking hyaluronan synthases 1 and 3. Excessive signaling leads to fibrosis in various organs, making this pathway a target for antifibrotic therapies.
From transforming growth factor beta receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does TGFBR1 kinase activity drive fibrosis? | Knockout of TGFBR1 in fibroblasts |
| How does TGFBR2 loss affect retinoblastoma? | TGFBR2 knockout in retinoblastoma cells |
| Can a point mutation in TGFBR1 mimic inhibitor resistance? | Point mutation knock-in in cancer cells |
| What is the effect of TGFB1 overexpression? | Overexpression in transgenic mice |
| How does HAS1/3 deletion alter TGF-beta signaling? | Double knockout mice |
| Does activin A bind TGFBR1 with high affinity? | Knock-in of reporter tags for binding assays |
How to Study the transforming growth factor beta receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| X-ray crystallography | 3D structure of receptor-ligand complex | Drug design |
| Molecular dynamics simulation | Binding dynamics and affinity | Predicting promiscuous interactions |
| Surface plasmon resonance | Real-time binding kinetics | Ligand-receptor affinity measurement |
| Radioligand binding | Specific binding sites | Receptor quantification |
| Immunofluorescence | Cellular localization of receptors | Internalization studies |
| Western blot | Phosphorylation of Smads | Pathway activation |
| CRISPR knockout screen | Genes affecting signaling | Identify novel regulators |
Structural Biology
X-ray crystallography and cryo-EM can resolve the structure of ligand-receptor complexes, as demonstrated for TGFBR1 with inhibitor SB505124. These methods reveal atomic details of binding interfaces and guide drug design.
Computational Modeling
Molecular dynamics simulations and docking studies model the formation of TGF-beta and activin A receptor complexes, predicting binding affinities and promiscuity. This complements experimental structural data.
Cell-Based Binding Assays
Radioligand binding assays and surface plasmon resonance (SPR) measure ligand-receptor interactions in vitro. Internalization assays track receptor trafficking after binding.
CRISPR Screening
Genome-wide CRISPR knockout screens can identify genes that modulate TGF-beta receptor binding and downstream signaling, uncovering novel regulators.
How CRISPR Can Be Used to Study GO:0005160 transforming growth factor beta receptor binding
Knockout
CRISPR knockout of TGFBR1, TGFBR2, or ligands like TGFB1 can abolish receptor binding and downstream signaling, providing causal insights. For example, TGFBR2 knockout in retinoblastoma cells mimics the lack of receptor expression seen in patients.
Point Mutation
Introducing point mutations in the kinase domain of TGFBR1 can mimic clinical mutations or confer resistance to inhibitors like SB505124, allowing study of drug resistance mechanisms.
Knock-in
Knock-in of tagged receptors (e.g., GFP-TGFBR2) enables live-cell imaging of receptor trafficking and binding dynamics. Knock-in of disease-associated mutations can model human disorders.
Overexpression
Overexpression of TGFB1 or constitutively active TGFBR1 in cell lines or transgenic mice can induce fibrosis or cancer phenotypes, validating the role of enhanced receptor binding in disease.
How EDITGENE Supports transforming growth factor beta receptor binding Research
Researchers studying transforming growth factor beta receptor binding-related genes often need to determine whether a candidate gene is causally involved in a specific signaling outcome or disease phenotype. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell and animal models, enabling functional validation of genes in the TGF-beta pathway.
Contact EDITGENE today to design your custom CRISPR model for transforming growth factor beta receptor binding research.
Frequently Asked Questions About transforming growth factor beta receptor binding
What is GO:0005160?
GO:0005160 is the Gene Ontology molecular function term for transforming growth factor beta receptor binding, defined as binding to a TGF-beta receptor.
What genes are involved in transforming growth factor beta receptor binding?
Key genes include TGFB1, TGFBR1, TGFBR2, ACVR1, ACVR2A, and INHBA, which encode ligands and receptors in the TGF-beta superfamily.
What diseases are associated with TGF-beta receptor binding?
Diseases include cancer (e.g., retinoblastoma), renal arteriolar hyalinosis, and fibrosis.
How is TGF-beta receptor binding studied?
Methods include X-ray crystallography, computational modeling, binding assays, and CRISPR screens.
What are the synonyms for GO:0005160?
Synonyms include activin binding, inhibin binding, TGF-beta receptor binding, and TGFbeta receptor binding.
What is the role of TGF-beta receptor binding in wound healing?
It drives myofibroblast differentiation during skin wound healing, as shown in mouse models.
Can CRISPR be used to study TGF-beta receptor binding?
Yes, CRISPR knockout, knock-in, and point mutation models enable functional studies of receptor binding and signaling.
What is the structure of TGF-beta receptors?
They are serine/threonine kinase receptors that form heterotetrameric complexes upon ligand binding.
How does internalization affect TGF-beta signaling?
Internalization of ligand-receptor complexes can regulate signaling duration and intensity.
What inhibitors target TGF-beta receptor binding?
Kinase inhibitors like SB505124 target the type I receptor and block downstream signaling.
Conclusion
GO:0005160, transforming growth factor beta receptor binding, is a pivotal molecular function that initiates a broad spectrum of cellular responses. Its dysregulation underlies numerous diseases, making it a prime target for therapeutic intervention. Continued research using advanced CRISPR and structural approaches will further illuminate its mechanisms and enable the development of precise treatments.
References
- 1. Rodriguez Buitrago JA et al.. 2024. Human transforming growth factor β type I receptor in complex with kinase inhibitor SB505124.. Acta Crystallogr F Struct Biol Commun 80(Pt 11):314-319 PMID: 39441620
- 2. Wang Y et al.. 2022. Transforming Growth Factor-β Receptor-Mediated, p38 Mitogen-Activated Protein Kinase-Dependent Signaling Drives Enhanced Myofibroblast Differentiation during Skin Wound Healing in Mice Lacking Hyaluronan Synthases 1 and 3.. Am J Pathol 192(12):1683-1698 PMID: 36063901
- 3. Massagué J et al.. 1992. TGF-beta receptors.. Mol Reprod Dev 32(2):99-104 PMID: 1322148
- 4. Farmer SM et al.. 2021. Computational modeling of transforming growth factor β and activin a receptor complex formation in the context of promiscuous signaling regulation.. J Biomol Struct Dyn 39(14):5166-5181 PMID: 32597324
- 5. Chiasson VL et al.. 2012. Endothelial cell transforming growth factor-β receptor activation causes tacrolimus-induced renal arteriolar hyalinosis.. Kidney Int 82(8):857-66 PMID: 22495293
- 6. Massagué J et al.. 1986. Internalization of transforming growth factor-beta and its receptor in BALB/c 3T3 fibroblasts.. J Cell Physiol 128(2):216-22 PMID: 2874147
- 7. Budi EH et al.. 2017. Transforming Growth Factor-β Receptors and Smads: Regulatory Complexity and Functional Versatility.. Trends Cell Biol 27(9):658-672 PMID: 28552280
- 8. Horie K et al.. 1998. Lack of transforming growth factor-beta type II receptor expression in human retinoblastoma cells.. J Cell Physiol 175(3):305-13 PMID: 9572475
